Drug Profile
Research programme: orphan nuclear receptors - Japan Tobacco/Amgen
Alternative Names: Orphan nuclear receptors research programme - Japan Tobacco/AmgenLatest Information Update: 17 Dec 2003
Price :
$50
*
At a glance
- Originator Japan Tobacco; Tularik
- Developer Tularik
- Class Small molecules
- Mechanism of Action Liver X receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hypercholesterolaemia
Most Recent Events
- 17 Dec 2003 Discontinued - Preclinical for Hypercholesterolaemia in USA (unspecified route)
- 19 Jun 2001 Preclinical development for Hypercholesterolaemia in USA (Unknown route)
- 11 Mar 1999 New profile